Last reviewed · How we verify
VIB4920
VIB4920 is a Small molecule drug developed by Amgen. It is currently in Phase 2 development. Also known as: Dazodalibep, MEDI4920, dazodalibep.
VIB4920 is a CD40 ligand antagonist, a type of protein modality drug. It is being studied in a Phase 2a clinical trial for the prophylaxis of allograft rejection in adults receiving a kidney transplant.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Amgen is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | VIB4920 |
|---|---|
| Also known as | Dazodalibep, MEDI4920, dazodalibep |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- CD40L Antagonism in Rheumatoid Arthritis (RA) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity (PHASE3)
- A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State (PHASE3)
- VIBRANT: VIB4920 for Active Lupus Nephritis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome (PHASE2)
- A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis (PHASE1)
- A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant (PHASE2)
- A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIB4920 CI brief — competitive landscape report
- VIB4920 updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about VIB4920
What is VIB4920?
Who makes VIB4920?
Is VIB4920 also known as anything else?
What development phase is VIB4920 in?
Related
- Manufacturer: Amgen — full pipeline
- Also known as: Dazodalibep, MEDI4920, dazodalibep
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing